Dare Bioscience to Launch FloraSync LF5 in June, Seeks Additional Funding
Dare Bioscience plans to launch FloraSync LF5 in June 2026 as its first direct product revenue, targeting women’s health gaps while its topical arousal cream Dare to Play has faced state-specific registration delays. The firm relies on non-dilutive grants but lacks 12 months of capital and must raise funds.
1. Pipeline and Product Launch Plans
Dare Bioscience has a pipeline focused on women’s health and will launch FloraSync LF5 in June 2026 as its first direct product revenue, marking entry into market and leveraging a dual-path strategy of 503b compounding and FDA approvals.
2. Commercialization Delays for Dare to Play
Nationwide rollout of the Dare to Play topical arousal cream has been delayed by state-specific registration requirements and manufacturing readiness, with 28 state registrations completed but additional data pending before dispensing is allowed in some jurisdictions.
3. Financial Runway and Funding Needs
While non-dilutive grants fund several programs, the company currently lacks a full 12-month capital runway based on operations alone and plans to seek additional financing to support commercial infrastructure and ongoing development.
4. Oviprine Development and FDA Engagement
Oviprine, a potential first-in-category fertility treatment, remains in clinical trials with enrollment-dependent timing and requires further FDA engagement, suggesting possible delays before market entry.